𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer

✍ Scribed by Dean A. Fennell; Jeremy P.C. Steele; Jonathan Shamash; Sarah E. Slater; Michael T. Sheaff; Paula Wells; Robin M. Rudd; Justin Stebbing

Publisher
John Wiley and Sons
Year
2007
Tongue
French
Weight
87 KB
Volume
121
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

There is no standard therapy for relapsed small cell lung cancer (rSCLC). We evaluated the efficacy and toxicity of a new triplet consisting of irinotecan (100 mg/m^2^ Days 1 and 15 q28), cisplatin (40 mg/m^2^ Days 1 and 15 q28) and mitomycin (6 mg/m^2^ d1 q28) administered to a maximum of 6 cycles in individuals with rSCLC that had relapsed following first line treatment. Partial remisions were observed in 35% and progression in 30% of patients. Progression free survival measured 4.5 months (95% CI 0.8–8.2) and overall survival was 7.8 months (95% CI 5.3–10.3). QoL showed improvement in activity symptoms and stabilization of physical symptoms. As IPM was a well‐tolerated regimen with activity in rSCLC, a phase III trial comparing this triplet with other regimens in this setting is warranted. Β© 2007 Wiley‐Liss, Inc.

πŸ“œ SIMILAR VOLUMES

Phase II trial of irinotecan and cisplat
Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer
✍ Joo Hyuk Sohn; Yong Wha Moon; Chang Geol Lee; Gwi Eon Kim; Kyung Young Chung; Jo πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 91 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. A Phase II trial of irinotecan and cisplatin (IP) with early concurrent radiotherapy was performed in limited‐disease small‐cell lung cancer (LD‐SCLC) to evaluate the efficacy and toxicity. ## METHODS. For untreated LD‐SCLC patients, irinotecan (60 mg/m^2^, Days 1, 8,

Phase II trial of edatrexate in small ce
Phase II trial of edatrexate in small cell lung cancer
✍ Martin Wiesenfeld; James R. Jett; John Q. Su; Theodore A. Braich; Carl G. Kardin πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 435 KB πŸ‘ 2 views
Phase II trial of etoposide and cisplati
Phase II trial of etoposide and cisplatin for refractory small cell lung cancer: A cancer and leukemia group B study
✍ Graziano, Stephen L. ;Lee, Kewchang ;Propert, Kathleen J. ;Tinsley, Roger ;Hayes πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 466 KB

## Abstract A phase II trial of etoposide and cisplatin for patients with previously treated small cell lung cancer was carried out by CALGB from June 1983 to May 1984. Thirty‐five evaluable patients who had failed one prior chemotherapy regimen were treated with etoposide 80 mg/m^2^ and cisplatin